Prothrombotic markers in asymptomatic dyslipidemic subjects

Journal of Thrombosis and Thrombolysis

Volumn 31, Issue 1, 2011, Pages 27-36

  Karasek, David ^a   Vaverkova, Helena ^a   Halenka, Milan ^a   Jackuliakova, Dagmar ^a   Frysak, Zdenek ^a   Slavik, Ludek ^a   Novotny, Dalibor ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Dyslipidemia; Insulin resistance; Intima media thickness; Plasminogen activator inhibitor 1; Tissue plasminogen activator; Von Willebrand factor

Indexed keywords

APOLIPOPROTEIN B; BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; BLOOD PRESSURE; COMMON CAROTID ARTERY; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; MALE; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGE FACTORS; AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; THROMBOSIS;

EID: 78651473765     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0474-4     Document Type: Article

References (79)

1. AD Sniderman 2004 Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorythm Curr Opin Lipidol 15 433 438 1:CAS:528:DC%2BD2cXlsV2hsrY%3D 10.1097/01.mol.0000137220. 39031.3b 15243216
2. B Lamarche S Moorjani PJ Lupien B Cantin PM Bernard GR Dagenais JP Després 1996 Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five-year follow-up of men in Québec cardiovascular study Circulation 94 273 278 1:STN:280:DyaK28zhsValtg%3D%3D 8759066
3. G Walldius I Jungner I Holme AH Aastveit W Kolar E Steiner 2001 High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2026 2033 1:CAS:528:DC%2BD38XhsFSn 10.1016/S0140-6736(01)07098-2 11755609
4. PJ Talmud E Hawe GJ Miller SE Humphries 2002 Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men Arterioscler Thromb Vasc Biol 22 1918 1923 1:CAS:528:DC%2BD38Xot1OitLY%3D 10.1161/01.ATV.0000035521.22199.C7 12426225
5. AD Sniderman CD Furberg A Keech JE Roeters van Lennep J Frohlich I Jungner G Walldius 2003 Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment Lancet 361 777 780 1:CAS:528: DC%2BD3sXhs1WktL4%3D 10.1016/S0140-6736(03)12663-3 12620753
6. H Vaverkova D Karasek D Novotny D Jackuliakova J Lukes M Halenka J Frohlich 2009 Apolipoprotein B versus LDL-cholesterol: association with other risk factors for atherosclerosis Clin Biochem 42 1246 1251 1:CAS:528: DC%2BD1MXptVSitbw%3D 10.1016/j.clinbiochem.2009.05.004 19450572
7. H Campos JJ Genest Jr E Blijlevens JR McNamara JL Jenner JM Ordovas PW Wilson EJ Schaefer 1992 Low density lipoprotein particle size and coronary artery disease Arterioscler Thromb 12 187 195 1:STN:280:DyaK387otF2juw%3D%3D 1543692
8. MA Austin BL Rodriguez B McKnight MJ McNeely KL Edwards JD Curb DS Sharp 2000 Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men Am J Cardio 86 412 416 1:CAS:528:DC%2BD3cXls1GitL8%3D 10.1016/S0002-9149(00)00956-5
9. EW Kraegen GJ Cooney J Ye AL Thompson 2001 Triglycerides, fatty acids and insulin resistance - hyperinsulinemia Exp Clin Endocrinol Diabetes 109 S516 S526 1:STN:280:DC%2BD38%2FitV2ntQ%3D%3D 10.1055/s-2001-15114 11453039
10. P McBride 2008 Triglycerides and risk for coronary artery disease Curr Atheroscler Rep 10 386 390 1:CAS:528:DC%2BD1cXhtFemtb3I 10.1007/s11883-008-0060- 9 18706279
11. I Lemieux P Poirier J Bergeron N Alméras B Lamarche B Cantin GR Dagenais JP Després 2007 Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? Can J Cardiol 23 Suppl B 23B 31B 17932584
12. A Schumacher I Seljeflot L Sommervoll B Christensen JE Otterstad H Arnesen 2002 Increased levels of endothelial haemostatic markers in patients with coronary heart disease Thromb Res 105 25 31 1:CAS:528:DC%2BD38XhsFansrk%3D 10.1016/S0049-3848(01)00399-1 11864703
13. AM Thogersen JH Jansson K Boman TK Nilsson L Weinehall F Huhtasaari G Hallmans 1998 High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor Circulation 98 2241 2247 1:CAS:528:DyaK1cXotVeku7w%3D 9826309
14. PE Morange C Simon MC Alessi G Luc D Arveiler J Ferrieres P Amouyel A Evans P Ducimetiere I Juhan-Vague PRIME Study Group 2004 Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study Circulation 109 1343 1348 1:CAS:528:DC%2BD2cXitFWrsLc%3D 10.1161/01.CIR.0000120705.55512.EC 15023872
15. PM Mannucci L Bernardinelli L Foco M Galli F Ribichini M Tubaro F Peyvandi 2005 Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women J Thromb Haemost 3 280 286 1:CAS:528:DC%2BD2MXitlSqsrY%3D 10.1111/j.1538-7836.2005.01116.x 15670033
16. B Wiman T Andersson J Hallqvist C Reuterwall A Ahlbom U deFaire 2000 Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study Arterioscler Thromb Vasc Biol 20 2019 2023 1:CAS:528:DC%2BD3cXmtFGqtLs%3D 10938026
17. AR Folsom KK Wu WD Rosamond AR Sharrett LE Chambless 1997 Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study Circulation 96 1102 1108 1:STN:280:DyaK2svjtFCgsw%3D%3D 9286936
18. SG Thompson J Kienast SD Pyke F Haverkate JC van de Loo 1995 Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group N Engl J Med 332 635 641 1:STN:280:DyaK2M7ksl2gsQ%3D%3D 10.1056/NEJM199503093321003 7845427
19. WB Kannel 2005 Overview of hemostatic factors involved in atherosclerotic cardiovascular disease Lipids 40 1215 1220 1:CAS:528:DC%2BD28XhtVCht7c%3D 10.1007/s11745-005-1488-8 16477805
20. G Geroulakos DJ O'Gorman E Kalodiki DJ Sheridan AN Nicolaides 1994 The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease Eur Heart J 15 781 785 1:STN:280:DyaK2cznsVensg%3D%3D 8088266
21. A Visonà R Pesavento L Lusiani A Bonanome C Cernetti M Rossi P Maiolino A Pagnan 1996 Intimal medial thickening of common carotid artery as indicator of coronary artery disease Angiology 47 61 66 10.1177/ 000331979604700109 8546347
22. ML Bots AW Hoes PJ Koudstaal A Hofman DE Grobbee 1997 Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study Circulation 96 1432 1437 1:STN:280:DyaK2svlvFGlug%3D%3D 9315528
23. C Bonithon-Kopp PJ Touboul C Berr C Leroux F Mainard D Courbon P Ducimetière 1996 Relation of intima-media thickness to atherosclerotic plaques in carotid arteries. The Vascular Aging (EVA) Study Arterioscler Thromb Vasc Biol 16 310 316 1:STN:280:DyaK287oslOnug%3D%3D 8620348
24. S Rosfors S Hallerstam K Jensen-Urstad M Zetterling C Carlstrom 1998 Relationship between intima-media thickness in the common carotid artery and atherosclerosis in the carotid bifurcation Stroke 29 1378 1382 1:STN:280:DyaK1czitFyhtQ%3D%3D 9660390
25. ML Bots A Hofman DE Grobbee 1994 Common carotid intima-media thickness and lower extremity arterial atherosclerosis. The Rotterdam Study Arterioscler Thromb 14 1885 1891 1:STN:280:DyaK2M%2FntF2rsQ%3D%3D 7981175
26. ML Bots PT de Jong A Hofman DE Grobbee 1997 Left, right, near or far wall common carotid intima-media thickness measurements: associations with cardiovascular disease and lower extremity arterial atherosclerosis J Clin Epidemiol 50 801 807 1:STN:280:DyaK2szpslegsg%3D%3D 10.1016/S0895-4356(97)00059- 0 9253391
27. P Poredos 2004 Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis Vasc Med 9 46 54 10.1191/1358863x04vm514ra 15230488
28. HT Nguyen-Thanh BS Benzaquen 2009 Screening for subclinical coronary artery disease measuring carotid intima media thickness Am J Cardiol 104 1383 1388 10.1016/j.amjcard.2009.07.005 19892054
29. PN Demacker MJ Veerkamp SJ Bredie SM Marcovina J de Graaf AF Stalenhoef 2000 Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia Atherosclerosis 153 483 490 1:CAS:528:DC%2BD3MXlslOisQ%3D%3D 10.1016/S0021-9150(00)00432-9 11164438
30. BA Griffin DJ Freeman GW Tait J Thomson MJ Caslake CJ Packard J Shepherd 1994 Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk Atherosclerosis 106 241 253 1:CAS:528: DyaK2cXksFGjsb4%3D 10.1016/0021-9150(94)90129-5 8060384
31. JH Contois JR McNamara CJ Lammi-Keefe PW Wilson T Massov EJ Schaefer 1996 Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study Clin Chem 42 515 523 1:CAS:528:DyaK28Xit1Ontbk%3D 8605667
32. B Lamarche JP Després S Moorjani B Cantin GR Dagenais PJ Lupien 1995 Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study) Am J Cardiol 75 1189 1195 1:STN:280:DyaK2M3pslCnsg%3D%3D 10.1016/S0002-9149(99)80760-7 7778537
33. PW Connelly M Poapst J Davignon S Lussier-Cacan B Reeder R Lessard RA Hegele A Csima 1999 Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group Can J Cardiol 15 409 418 1:CAS:528:DyaK1MXjtlKms7Y%3D 10322250
34. PS Bachorik KL Lovejoy MD Carroll CL Johnson 1997 Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III) Clin Chem 43 2364 2378 1:CAS:528:DyaK1cXis1Kiug%3D%3D 9439456
35. DR Matthews JP Hosker AS Rudenski BA Naylor DF Treacher RC Turner 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 412 419 1:CAS:528:DyaL2MXlslKnu7k%3D 10.1007/BF00280883 3899825
36. HC Kwaan 1992 The biologic role of components of the plasminogen-plasmin system Prog Cardiovasc Dis 34 309 316 1:CAS:528:DyaK38XksVGjurs%3D 10.1016/0033-0620(92)90036-Y 1531879
37. HR Lijnen 1996 Pathophysiology of the plasminogen/plasmin system Int J Clin Lab Res 26 1 6 1:CAS:528:DyaK28XjsVensLg%3D 10.1007/BF02644767 8739849
38. A Nordehem B Wiman 1998 Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes Scand J Clin Lab Investig 58 475 483 10.1080/00365519850186274
39. WL Chandler CL Trimble SC Loo D Mornin 1990 Effect of PAI-1 levels on molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma Blood 76 930 937 1:CAS:528:DyaK3MXjvFWh 2118399
40. L Mussoni L Mannucci M Sirtori M Camera P Maderna L Sironi E Tremoli 1992 Hypertriglyceridemia and regulation of fibrinolytic activity Arterioscler Thromb 12 19 27 1:STN:280:DyaK387hvVOmtg%3D%3D 1310024
41. I Mertens I Lemieux A Verrijken JP Després LF Van Gaal 2008 PAI-1 activity, but not fibrinogen or von Willebrand factor, is inversely related to LDL particle size in type 2 diabetes Diabetes Metab Res Rev 24 141 147 1:CAS:528:DC%2BD1cXjtlemtro%3D 10.1002/dmrr.779 17922472
42. N Sattar K Williams AD Sniderman R D'Agostino Jr SM Haffner 2004 Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study Circulation 110 2687 2693 1:CAS:528:DC%2BD2cXos1Ghtrk%3D 10.1161/01.CIR. 0000145660.60487.94 15492304
43. K Williams AD Sniderman N Sattar R D'Agostino Jr LE Wagenknecht SM Haffner 2003 Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS) Circulation 108 2312 2316 1:CAS:528:DC%2BD3sXos1Smsr0%3D 10.1161/01.CIR.0000097113.11419.9E 14581403
44. MC Alessi I Juhan-Vague T Kooistra PJ Declerck D Collen 1988 Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2 Thromb Haemost 60 491 494 1:CAS:528: DyaL1MXht1yqt78%3D 3149048
45. T Kooistra PJ Bosma HA Töns AP van den Berg P Meyer HM Princen 1989 Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes Thromb Haemost 62 723 728 1:CAS:528:DyaK3cXhs1Gqtw%3D%3D 2683191
46. DJ Schneider PM Absher MA Ricci 1997 Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells Circulation 96 2868 2876 1:CAS:528:DyaK2sXnvFajsLc%3D 9386151
47. K Landin L Tengborn J Chmielewska H von Schenck U Smith 1991 The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man Thromb Haemost 65 130 133 1:CAS:528:DyaK3MXlsFWitLk%3D 1905068
48. H Vuorinen-Markkola I Puhakainen H Yki-Järvinen 1992 No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man Thromb Haemost 67 117 120 1:CAS:528:DyaK38Xit1ylt7w%3D 1615465
49. PJ Grant EK Kruithof CP Felley JP Felber F Bachmann 1990 Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man Clin Sci (Lond) 79 513 516 1:CAS:528:DyaK3MXisVWjsrs%3D
50. J Calles-Escandon SA Mirza BE Sobel DJ Schneider 1998 Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects Diabetes 47 290 293 1:CAS:528:DyaK1cXntVOhtA%3D%3D 10.2337/diabetes.47.2.290 9519730
51. MC Alessi F Peiretti P Morange M Henry G Nalbone I Juhan-Vague 1997 Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease Diabetes 46 860 867 1:CAS:528:DyaK2sXjtVGntb0%3D 10.2337/diabetes.46.5.860 9133556
52. G He SB Pedersen JM Bruun AS Lihn PF Jensen B Richelsen 2003 Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects Horm Metab Res 35 178 182 1:CAS:528:DC%2BD3sXjvFOrsbk%3D 10.1055/s-2003-39078 12734779
53. JP Bastard L Piéroni B Hainque 2000 Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance Diabetes Metab Res Rev 16 192 201 1:CAS:528:DC%2BD3cXltFWhtLg%3D 10.1002/1520-7560(200005/06)16: 3<192::AID-DMRR114>3.0.CO;2-G 10867719
54. P Vague I Juhan-Vague V Chabert MC Alessi C Atlan 1989 Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women Metabolism 38 913 915 1:STN:280:DyaL1MzmsVarsQ%3D%3D 10.1016/0026-0495(89)90241- 2 2505018
55. K Landin L Stigendal E Eriksson M Krotkiewski B Risberg L Tengborn U Smith 1990 Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor Metabolism 39 1044 1048 1:CAS:528:DyaK3cXlsFSju7g%3D 10.1016/0026-0495(90)90164-8 2215252
56. P Eriksson S Reynisdottir F Lönnqvist V Stemme A Hamsten P Arner 1998 Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals Diabetologia 41 65 71 1:CAS:528:DyaK1cXnvFyhtQ%3D%3D 10.1007/s001250050868 9498632
57. P Eriksson V Van Harmelen J Hoffstedt P Lundquist H Vidal V Stemme A Hamsten P Arner S Reynisdottir 2000 Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals Thromb Haemost 83 545 548 1:CAS:528:DC%2BD3cXjtFWltb0%3D 10780314
58. EJ Giltay JM Elbers LJ Gooren JJ Emeis T Kooistra H Asscheman CD Stehouwer 1998 Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration Arterioscler Thromb Vasc Biol 18 1716 1722 1:CAS:528: DyaK1cXnvFShtr4%3D 9812909
59. I Mertens M Van der Planken B Corthouts M Wauters F Peiffer I De Leeuw L Van Gaal 2001 Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women Horm Metab Res 33 602 607 1:CAS:528:DC%2BD3MXpt1Snu74%3D 10.1055/s-2001-17907 11607880
60. B Janand-Delenne C Chagnaud D Raccah MC Alessi I Juhan-Vague P Vague 1998 Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women Int J Obes Relat Metab Disord 22 312 317 1:STN:280:DyaK1c3jslentA%3D%3D 10.1038/sj.ijo.0800585 9578235
61. M Cigolini G Targher JC Seidell M Tonoli R Schiavon G Agostino G De Sandre 1995 Relationships of blood pressure to fibrinolysis: influence of anthropometry, metabolic profile and behavioural variables J Hypertens 13 659 666 1:CAS:528:DyaK2MXnsFKisb0%3D 10.1097/00004872-199506000-00013 7594424
62. JR Jeng WH Sheu CY Jeng SH Huang SM Shieh 1996 Impaired fibrinolysis and insulin resistance in patients with hypertension Am J Hypertens 9 484 490 1:STN:280:DyaK28zisl2msg%3D%3D 10.1016/0895-7061(95)00442-4 8735180
63. WR Litchfield N Brown DE Vaughan 1997 Plasminogen activator inhibitor 1 in diabetes and hypertension Curr Opin Endocrinol Diabetes 4 233 238 10.1097/00060793-199706000-00009
64. R Fogari A Zoppi 2006 Antihypertensive drugs and fibrinolytic function Am J Hypertens 19 1293 1299 1:CAS:528:DC%2BD28Xht12rt7%2FO 10.1016/j.amjhyper. 2006.04.013 17161777
65. C Karlsson K Lindell M Ottosson L Sjöström B Carlsson LM Carlsson 1998 Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II J Clin Endocrinol Metab 83 3925 3929 1:CAS:528:DyaK1cXntlOitrc%3D 10.1210/jc.83.11.3925 9814470
66. P Schling H Mallow A Trindl G Löffler 1999 Evidence for a local renin angiotensin system in primary cultured human preadipocytes Int J Obes Relat Metab Disord 23 336 341 1:CAS:528:DyaK1MXjtVKjurg%3D 10.1038/sj.ijo. 0800821 10340809
67. O Lenz A Fornoni 2008 Renin-angiotensin system blockade and diabetes: moving the adipose organ from the periphery to the center Kidney Int 74 851 853 1:CAS:528:DC%2BD1cXhtFWhtrjO 10.1038/ki.2008.391 18794817
68. DS Frankel JB Meigs JM Massaro PW Wilson CJ O'Donnell RB D'Agostino GH Tofler 2008 Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the Framingham Offspring Study Circulation 118 2533 2539 1:CAS:528:DC%2BD1cXhsVerur3F 10.1161/CIRCULATIONAHA.108.792986 19029465
69. JB Meigs CJ O'Donnell GH Tofler EJ Benjamin CS Fox I Lipinska DM Nathan LM Sullivan RB D'Agostino PW Wilson 2006 Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study Diabetes 55 530 537 1:CAS:528:DC%2BD28XhsFajsbw%3D 10.2337/diabetes.55.02.06. db05-1041 16443791
70. T Ostergård B Nyholm TK Hansen LM Rasmussen J Ingerslev KE Sørensen HE Bøtker B Saltin O Schmitz 2006 Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training Metabolism 55 1508 1515 10.1016/j.metabol.2006.06.024 17046554
71. A Natali E Toschi S Baldeweg D Ciociaro S Favilla L Saccà E Ferrannini 2006 Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes Diabetes 55 1133 1140 1:CAS:528:DC%2BD28XjsVGmur4%3D 10.2337/diabetes.55.04.06.db05-1076 16567539
72. CH Foss E Vestbo A Frøland J Ingerslev HJ Gjessing CE Mogensen EM Damsgaard 2002 Insulin resistance is accompanied by increased von Willebrand factor levels in nondiabetic women: a study of offspring of type 2 diabetic subjects compared to offspring of nondiabetic subjects J Intern Med 252 155 163 1:CAS:528:DC%2BD38XntFGku78%3D 10.1046/j.1365-2796.2002.01024.x 12190891
73. BG Seligman A Biolo CA Polanczyk JL Gross N Clausell 2000 Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia Diabetes Care 23 1395 1400 1:CAS:528: DC%2BD3cXnvV2jsrY%3D 10.2337/diacare.23.9.1395 10977040
74. AM Georgieva HT Cate ET Keulen R van Oerle JW Govers-Riemslag K Hamulyák CJ van der Kallen MM Van Greevenbroek TW De Bruin 2004 Prothrombotic markers in familial combined hyperlipidemia: evidence of endothelial cell activation and relation to metabolic syndrome Atherosclerosis 175 345 351 1:CAS:528:DC%2BD2cXlsl2gurk%3D 10.1016/j.atherosclerosis.2004.04.006 15262191
75. D Karásek H Vaverková M Halenka L Slavík D Novotný 2009 Endothelial haemostatic markers in members of families with familial combined hyperlipidemia Thromb Res 123 466 475 10.1016/j.thromres.2008. 02.011 18417194
76. L Daza M Aguirre M Jimenez R Herrera JJ Bollain 2007 Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors Clin Rheumatol 26 533 537 10.1007/s10067-006-0338-7 16758372
77. M Cortellaro D Baldassarre E Cofrancesco E Tremoli A Colombo C Boschetti R Paoletti 1996 Relation between hemostatic variables and increase of common carotid intima-media thickness in patients with peripheral arterial disease Stroke 27 450 454 1:STN:280:DyaK287nsFyltw%3D%3D 8610312
78. K Pawlak B Naumnik S Brzósko D Pawlak M Myśliwiec 2004 Oxidative stress-a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients Am J Nephrol 24 154 161 1:CAS:528:DC%2BD2cXht1ahtLo%3D 10.1159/000076244 14726627
79. JA Paramo O Beloqui I Colina J Diez J Orbe 2005 Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects J Thromb Haemost 3 662 664 1:STN:280:DC%2BD2M3gvFamsQ%3D%3D 10.1111/j.1538-7836.2005.01305.x 15842351